Publish in this journal
Journal Information
Vol. 109. Num. 6.July - August 2018
Pages e37-e46Pages 465-576
Share
Share
Download PDF
More article options
ePub
Visits
1
Vol. 109. Num. 6.July - August 2018
Pages e37-e46Pages 465-576
Original Article
DOI: 10.1016/j.adengl.2018.05.015
Papulopustular Rosacea: Response to Treatment with Oral Azithromycin
Rosácea papulopustulosa: respuesta al tratamiento con azitromicina oral
Visits
1
M. Lova Navarro
Corresponding author
lovamiguel@gmail.com

Corresponding author.
, P. Sánchez-Pedreño Guillen, A.M. Victoria Martínez, T. Martínez Menchón, R. Corbalán Vélez, J. Frías Iniesta
Servicio de Dermatología, Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
Related content
Actas Dermosifiliogr 2018;109:46910.1016/j.adengl.2018.03.017
M. Blanesblanes_marmar@gva.es
This item has received
1
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (4)
Table 1. Clinical Stages of Papulopustular Rosaceaa
Table 2. Levels of Clinical Response to Treatment With Oral Azithromycin in Patients With Papulopustular Rosaceaa
Table 3. Demographic Characteristics, Response to Conventional Treatment, and Changes in Clinical Staging in Patients With Papulopustular Rosacea Treated With Oral Azithromycin.
Table 4. Long-term Clinical Outcomes in Patients With Papulopustular Rosacea Following Treatment With Oral Azithromycin.
Show moreShow less
Abstract
Introduction

Oral tetracyclines and topical antibiotics have been used to treat papulopustular rosacea (PPR) for years, but it is not uncommon to find patients who do not respond to this standard treatment. In such refractory cases, oral azithromycin has proven to be an effective option.

Material and method

We conducted a prospective pilot study of 16 patients with PPR who were treated with oral azithromycin after a lack of response to oral doxycycline and metronidazole gel. At the first visit, the patients were assessed for baseline severity of PPR on a 4-point clinical scale and started on oral azithromycin. At the second visit, response to treatment in terms of improvement from baseline was evaluated on a 3-point scale. Patients were then scheduled for follow-up visits every 12 weeks to assess long-term effectiveness.

Results

All 16 patients experienced an improvement in their PPR following treatment with oral azithromycin. Eight weeks after completion of treatment, 14 patients (87.5%) showed complete or almost complete recovery (slight or no residual redness and complete clearance of papules and pustules). Only 2 patients experienced a new episode of inflammatory PPR lesions during follow-up.

Conclusions

The findings of this pilot study suggest that oral azithromycin could be a very effective short-term and long-term treatment for RPP resistant to conventional treatment.

Keywords:
Papulopustular rosacea
Azithromycin
Treatment
Resumen
Introducción

El tratamiento de la rosácea papulopustulosa (RPP) ha consistido durante años en el uso de tetraciclinas orales y antibióticos tópicos. Pero no es infrecuente encontrar casos de RPP resistentes al tratamiento convencional. Azitromicina oral ha demostrado ser una opción eficaz para estos pacientes no respondedores.

Material y método

Se realizó un estudio piloto prospectivo con 16 pacientes con RPP no respondedores al tratamiento convencional (doxiciclina oral y metronidazol gel) que recibieron tratamiento con azitromicina oral. En la visita inicial (visita 1) se realizó una valoración basal del estadio clínico de la RPP, según 4 niveles de gravedad progresiva, y se inició tratamiento con azitromicina oral. A las 8 semanas de finalizar el tratamiento (visita 2) se evaluó la respuesta clínica según 3 niveles de mejoría respecto al estadio clínico basal. Posteriormente, para evaluar la eficacia de azitromicina oral a largo plazo, se realizaron visitas periódicas cada 12 semanas.

Resultados

Todos los pacientes que recibieron tratamiento con azitromicina oral mejoraron de su RPP. A las 8 semanas de finalizar el tratamiento se objetivó un eritema facial residual débil o nulo, con desaparición completa de las pápulas y/o pústulas en el 87,5% de los pacientes. En cuanto al mantenimiento de la eficacia a largo plazo, únicamente 2 pacientes presentaron una recidiva de lesiones inflamatorias de RPP.

Conclusiones

Los resultados de nuestro estudio evidencian que azitromicina oral podría ser un fármaco de gran eficacia a corto y largo plazo para el manejo de aquellos casos de RPP resistentes al tratamiento convencional.

Palabras clave:
Rosácea papulopustulosa
Azitromicina
Tratamiento

Article

These are the options to access the full texts of the publication Actas Dermo-Sifiliográficas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Dermo-Sifiliográficas (English Edition)

Contact
Telephone
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
902 88 87 40
Calls from outside Spain
+34 932 418 800
E-mail
Idiomas
Actas Dermo-Sifiliográficas (English Edition)

Subscribe to our Newsletter

Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?